Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases

Ferroptosis plays an important role in the occurrence and development of many diseases, including neurodegenerative diseases. Thus, ferroptosis inhibitors able to cross the blood-brain barrier may have therapeutic potential. The best ferroptosis inhibitors so far are lipophilic radical trapping antioxidants (RTAs) that block lipid peroxidation in membranes. Several generations of ferrostatins have been synthesized, among which <b>UAMC-3203</b> showed high potency in animal models with improved properties compared to ferrostatin-1. To further improve its pharmacokinetics properties, drug-likeness, and permeability, we modified <b>UAMC-3203</b> by decreasing the size of the molecule and reducing its polarity by replacing the sulfonamide first by amide groups and subsequently by isosteric oxazoles. Herein, we present the design, synthesis, and biological evaluation of a novel series of oxazole RTAs with high potency, excellent oral bioavailability, and high concentrations in brain tissue.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-02-06
DOI
https://doi.org/10.1021/acs.jmedchem.4c03149
Citations
9
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
13.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases

Koen Augustyns, Emily Van San, Greta Klejborowska, Maya Berg et al.
9 citations
Journal of Medicinal Chemistry
Ferroptosis and cancer prognosis
13.67
article

Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases

Koen Augustyns, Emily Van San, Greta Klejborowska, Maya Berg, Ashley M. Toye, Pieter Van der Veken, Behrouz Hassannia, Camilla Scarpellini, Hans De Winter, Caroline Lanthier, Tom Vanden Berghe, Magali Walravens, Karolina Musiałek
article en
9 citations

Abstract

Ferroptosis plays an important role in the occurrence and development of many diseases, including neurodegenerative diseases. Thus, ferroptosis inhibitors able to cross the blood-brain barrier may have therapeutic potential. The best ferroptosis inhibitors so far are lipophilic radical trapping antioxidants (RTAs) that block lipid peroxidation in membranes. Several generations of ferrostatins have been synthesized, among which <b>UAMC-3203</b> showed high potency in animal models with improved properties compared to ferrostatin-1. To further improve its pharmacokinetics properties, drug-likeness, and permeability, we modified <b>UAMC-3203</b> by decreasing the size of the molecule and reducing its polarity by replacing the sulfonamide first by amide groups and subsequently by isosteric oxazoles. Herein, we present the design, synthesis, and biological evaluation of a novel series of oxazole RTAs with high potency, excellent oral bioavailability, and high concentrations in brain tissue.

Journal of Medicinal ChemistryVol. 68(4)
University of Antwerp (BE), Ghent University Hospital (BE), Ghent University (BE), VIB-UGent Center for Inflammation Research (BE), Pharmaceutical Biotechnology (Czechia) (CZ), Adam Mickiewicz University in Poznań (PL)
European Commission, Fonds Wetenschappelijk Onderzoek, Fondation Charcot, Universiteit Antwerpen, Vlaamse regering, Fondation contre le Cancer, H2020 Marie Skłodowska-Curie Actions
Openalex Percentile: Top 1%
Ferroptosis and cancer prognosis
13.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.